Show simple item record

dc.contributor.authorCao, B. et al.
dc.date.accessioned2020-04-02T21:00:30Z
dc.date.available2020-04-02T21:00:30Z
dc.date.issued2020-03-18
dc.identifier.urihttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=trueen_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/919
dc.description.abstract[Methods] We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2 ) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2 ) to the fraction of inspired oxygen (Fio2 ) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectLopinaviren_US
dc.subjectRitonaviren_US
dc.titleA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19en_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategoryProtect Health Care Workers / Proteger la Salud de los Trabajadoresen_US
dc.relation.ispartofjournalNew England Journal of Medicineen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record